Kodiak Sciences: BEACON Phase 3 tarcocimab meets primary endpoint in retinal vein occlusion

Kodiak Sciences Inc.

BEACON Phase 3 randomized 568 RVO patients to tarcocimab 5 mg q8w after 2 monthly loads vs aflibercept 2 mg q4w.
Primary endpoint of non-inferior BCVA change at week 24 met in BRVO (p=0.0004) and overall RVO (p=0.0243).
Tarcocimab dosed 4 times vs aflibercept 6 times in first 24 weeks, showing extended durability.
Safety favorable: low intraocular inflammation (1.4% vs 0.4%); no vasculitis or retinal artery occlusion.
Full primary results to be presented at ophthalmology congresses in September 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.